MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

United Therapeutics Corp

Отворен

СекторЗдравеопазване

289.69 -1.92

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

286.55

Максимум

297.62

Ключови измерители

By Trading Economics

Приходи

-7.8M

301M

Продажби

-13M

736M

P/E

Средно за сектора

11.884

57.333

EPS

6.19

Марж на печалбата

40.943

Служители

1,305

EBITDA

6.3M

424M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+29.27% upside

Дивиденти

By Dow Jones

Следващи печалби

30.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3.4B

13B

Предишно отваряне

291.61

Предишно затваряне

289.69

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

United Therapeutics Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2024 г., 15:14 ч. UTC

Значими двигатели на пазара

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28.01.2025 г., 10:30 ч. UTC

Топ новини

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Сравнение с други в отрасъла

Ценова промяна

United Therapeutics Corp Прогноза

Ценова цел

By TipRanks

29.27% нагоре

12-месечна прогноза

Среден 383.18 USD  29.27%

Висок 460 USD

Нисък 293 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за United Therapeutics Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

8

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

285.09 / 298.295Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.